Ocular Therapeutix’s Dextenza Gets FDA OK for Added Indication

Ocular Therapeutix says FDA approved a Supplemental New Drug Application for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication.

• Dextenza now approved for the treatment of both ocular inflammation and pain following ophthalmic surgery

Link to Statement: Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

©2019 Bloomberg L.P. All rights reserved. Used with permission